Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 6/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E637 SCHEMBL1870685 | 0.98 | KDM4E (0.55) | KDM4ELMNAAPPGABRA1GABRB2 | |
| E637 SCHEMBL41817 | 0.98 | KDM4E (0.55) | KDM4ELMNAAPPGABRA1GABRB2 | |
| E637 SCHEMBL27635951 | 0.96 | KDM4E (0.53) | KDM4ELMNAAPPGABRA1GABRB2 | |
| E637 SCHEMBL23309786 | 0.96 | KDM4E (0.53) | KDM4ELMNAAPPGABRA1GABRB2 | |
| E637 SCHEMBL8026696 | 0.96 | KDM4E (0.53) | KDM4ELMNAAPPGABRA1GABRB2 | |
| E637 SCHEMBL11019418 | 0.91 | LMNA (0.70) | KDM4ELMNAAPPMAPK1FTO | |
| E637 SCHEMBL14990891 | 0.91 | KDM4E (0.48) | KDM4ELMNAAPPGABRA1GABRB2 | |
| E637 SCHEMBL290806 | 0.89 | LMNA (0.72) | KDM4ELMNAAPPGABRA1GABRB2 | |
| SCHEMBL9625161 | 0.82 | KDM4E (0.52) | KDM4ELMNAAPPMAPK1FTO | |
| SCHEMBL9625506 | 0.79 | KDM4E (0.48) | KDM4ELMNAAPPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024030855-A2 | SYSTEMS AND METHODS FOR TRANSDERMAL PATCH DELIVERY | VITAMAX PATCH WHOLESALER LLC (US) | 2024-02-08 | — | — | WO | claimed |
| EP-0833627-B1 | IRON COMPOUNDS, COMPOSITIONS, METHODS OF MAKING THE SAME AND USES THEREOF | VITRA PHARMACEUTICALS LTD (GB) | 2004-08-18 | — | — | EP | claimed |
| US-20030069218-A1 | Iron compounds, compositions , methods of making the same and uses thereof | IRON THERAPEUTICS HOLDINGS AG (CH) | 2003-04-10 | — | — | US | claimed |
| EP-0833627-A2 | IRON COMPOUNDS, COMPOSITIONS, METHODS OF MAKING THE SAME AND USES THEREOF | Vitra Pharmaceuticals Ltd. (GB) | 1998-04-08 | — | — | EP | claimed |
| WO-1996041627-A2 | IRON COMPOUNDS, COMPOSITIONS, METHODS OF MAKING THE SAME AND USES THEREOF | VITRA PHARMACEUTICALS LTD (GB) | 1996-12-27 | — | — | WO | claimed |
| WO-2024030855-A2 | SYSTEMS AND METHODS FOR TRANSDERMAL PATCH DELIVERY | VITAMAX PATCH WHOLESALER LLC (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-0833627-B1 | IRON COMPOUNDS, COMPOSITIONS, METHODS OF MAKING THE SAME AND USES THEREOF | VITRA PHARMACEUTICALS LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6635631-B2 | Ferric iron complex of a hydroxypyrone ligand and a carboxylic acid; used to treat iron deficiency anemia | VITRA PHARMACEUTICALS, LTD. (GB) | 2003-10-21 | — | — | US | disclosed |
| US-20030069218-A1 | Iron compounds, compositions , methods of making the same and uses thereof | IRON THERAPEUTICS HOLDINGS AG (CH) | 2003-04-10 | — | — | US | disclosed |
| US-6339080-B1 | FOR THERAPY AND PROPHYLAXIS OF IRON DEFICIENCY DISORDERS INCLUDING IRON DEFICIENCY ANAEMIA | VITRA PHARMACEUTICALS LTD. (GB) | 2002-01-15 | — | — | US | disclosed |
| EP-0833627-A2 | IRON COMPOUNDS, COMPOSITIONS, METHODS OF MAKING THE SAME AND USES THEREOF | Vitra Pharmaceuticals Ltd. (GB) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996041627-A2 | IRON COMPOUNDS, COMPOSITIONS, METHODS OF MAKING THE SAME AND USES THEREOF | VITRA PHARMACEUTICALS LTD (GB) | 1996-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069218-A1 | Iron compounds, compositions , methods of making the same and uses thereof | SDHB, HAMP, FTH1 | KDM4E 1951/4885LMNA 1694/4885APP 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.